Momenta Pharmaceuticals Announces Issuance of U.S. Patent for Sialylation Technology

barbara.lempert CAMBRIDGE, Mass., June 25, 2013 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and ...

Intas Pharma, Roche Settle Xeloda Patent Case

barbara.lempert Intas Pharma Announces Settlement and License Agreement With Roche for XELODA® AHMEDABAD, India, June 25, 2013 /PRNewswire/ — Intas Pharmaceuticals ...

Pfizer’s Viagra patent in Europe expires today

Eric Palmer It's party time in Europe for generic drugmakers. The patent for Pfizer's erectile dysfunction drug Viagra falls off today and generics are expected to soon flood ...

Curis Announces U.S. Patent Issuance

barbara.lempert Curis Announces U.S. Patent Issuance Strengthening Intellectual Property Position of PI3K-HDAC Inhibitor CUDC-907 LEXINGTON, Mass., June 20, 2013 (GLOBE NEWSWIRE) ...

PhRMA Statement on Supreme Court Ruling in Patent Settlement Case

barbara.lempert WASHINGTON, D.C. (June 17, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President and General Counsel Mit Spears issued the ...

Novartis, Sun Pharma Gleevec patent battle moves to U.S.

Carly Helfand After years of struggling for intellectual property rights over cancer drug Glivec in India, Novartis ($ NVS) will now have to fight for patent protection in the U.S. ...

Anergis Files Provisional U.S. Patent on AllerDM Dust Mite Allergy Treatment

barbara.lempert Anergis Files Provisional U.S. Patent on AllerDM Dust Mite Allergy Treatment – Further expansion of the company’s product pipeline and patent estate – EPALINGES, ...

Credit Suisse says Pfizer patent win will discourage ‘at-risk’ launches

Eric Palmer Will Pfizer's big patent win against Teva Pharmaceutical Industries and India's Sun Pharma on Protonix discourage more "at-risk" drug launches of ...

How Much? Pfizer And Teva Reach $2.1B Deal Over Patent Dispute

esilverman This is an example of why at-risk launches are, well, risky. After nearly a decade of squabbling, Teva Pharmaceutical and Sun Pharmaceutical have agreed to settle ...

Fresenius Kabi Sues Actavis Over Diprivan Patent Challenge

barbara.lempert Actavis Confirms Generic Diprivan® Patent Challenge PARSIPPANY, N.J., June 7, 2013 /PRNewswire/ — Actavis, Inc. (NYSE: ACT) today confirmed that it ...

Provectus Receives Patent Allowance from U.S. Patent and Trademark Office

barbara.lempert Wednesday June 5, 2013 – Protects Novel Synthetic Process Used to Manufacture Rose Bengal and Related Xanthenes – Provectus has received allowance from ...

Indian officials may resurrect Pfizer’s Sutent patent

Carly Helfand Just as the situation for Big Pharma in India seemed its most dour, what with intellectual-property disputes and controversial price caps, India's Intellectual Property ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS